CONFIDENTIAL

Exhibit 10.17(a)

CONFIDENTIAL

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

TASK ORDER

MEDPACE Task Order Number: 20

MEDPACE Project Number: CHS-0214-4

This Task Order, dated November 8, 2013, is between Medpace, Inc. (“MEDPACE”), and Coherus Biosciences, Inc. (“SPONSOR”).

RECITALS:

WHEREAS, MEDPACE and SPONSOR have entered into that certain Master Services Agreement dated January 23, 2012 (the “Master Services Agreement”); and

WHEREAS, pursuant to the Master Services Agreement, MEDPACE has agreed to perform certain Services in accordance with Task Orders from time to time entered into by the Parties and SPONSOR and MEDPACE now desire to enter into such a Task Order; and

WHEREAS, MEDPACE and SPONSOR desire to engage Medpace to perform certain initial services (“Services”) as set forth hereinafter in connection with a A Double Blind, Randomized, Parallel Group, Active Control Study to Compare the Efficacy and Safety of CHS 0214 DP Versus Enbrel^® in Subjects With Chronic Plaque Psoriasis (PsO) (CHS-0214-04) (“Project”) , which is incorporated herein by reference;

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 1 of 15

IN WITNESS WHEREOF, the Parties have hereunto signed this Task Order effective as of the day and year first written above.

List of Appendices:

Appendix A: Scope of Work

Appendix B: Timeline

Appendix C: Budget

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 2 of 15

Appendix D: Payment Schedule

Appendix E: Transfer of Obligations

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 3 of 15

APPENDIX A: SCOPE OF WORK

SERVICES:

1.1 PROJECT START-UP

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 4 of 15

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 5 of 15

1.2 CLINICAL OPERATIONS

1.3 CLINICAL MONITORING

1.4 CLINICAL SAFETY

1.5 [***] SYSTEM

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 6 of 15

1.6 DATA MANAGEMENT

1.7 STATISTICAL ANALYSIS

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 7 of 15

APPENDIX B: TIMELINE

1. Timelines

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 8 of 15

APPENDIX C: BUDGET

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 9 of 15

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 10 of 15

APPENDIX D: PAYMENT SCHEDULE

[***] of this Task Order [***] of the total Pre-funded Expenses are due. [***]. SPONSOR shall pay such invoice within [***] of receipt. [***] received from SPONSOR, [***].

Additionally, [***] of the total estimated Pass-through Costs are due [***]. Pass-through Costs will be billed to SPONSOR [***].

Pass-through Costs and Pre-funded Expenses

Any sums quoted with respect to Pass-through Costs and Pre-funded Expenses [***]. While MEDPACE will [***]. Payments made to third parties are [***].

Pass-through Costs may include, but are not limited to, [***]. Costs associated with, [***] are as detailed in the table below.

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 11 of 15

MEDPACE will pass-through [***]. This will include [***].

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 12 of 15

Pre-funded Expenses

Pre-funded Expenses may include, but are not limited to, [***]. Investigator fees are [***]. The investigator fee amount [***]. The laboratory fee amount [***].

Additional Costs

[***]

All Direct Fees are [***]. All such changes [***]. After staff are assigned, [***].

Inflation

[***]

Currency and Exchange Rate

The currency of this Task Order is United States Dollars.

Medpace will invoice SPONSOR for Investigator payments [***]. The Direct Fees detailed in this Task Order were calculated using the [***]. [***]. [***].

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 13 of 15

Applicable Taxes

All Direct Fees, Pass-through Costs, and Pre-funded Expenses are quoted excluding any [***], which include but are not limited to [***], which may be payable to MEDPACE by SPONSOR.

[***] Certain information in this document has been omitted and filed separately with the Securities and

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 14 of 15

APPENDIX E: TRANFER OF OBLIGATIONS

CONFIDENTIAL

Directions: Complete a form for each clinical study where Sponsor obligations have been transferred in accordance with 21 CFR Part 312, Subpart D (Responsibilities of Sponsors). Forward the completed form to Sponsor’s Regulatory Affairs Department for submission to the applicable regulatory agencies.

		Medpace Task Order 20 Coherus Biosciences, Inc. CHS-0214-4 Start up Page 15 of 15